Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Business Model:
Revenue: $13.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Perceptive Advisors Information
Geographic Data
Address: 499 Park Ave
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Linkedin
Crunchbase
Metrics
2,160,524Website Global Rank
9,065Website Monthly Traffic
Twitter Followers
Description
Perceptive Advisors, LLC is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while making its investments. The firm typically invests in biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.
Contact Phone:
+16462055340
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2022 | MeiraGTx | Post-IPO Debt | 75M |
| 1/2021 | IsoPlexis | Series D | 85M |
| 4/2021 | Renovia | Series C | 0 |
| 1/2021 | IsoPlexis | Debt Financing | 50M |
| 11/2018 | Medicrea | Post-IPO Debt | 30M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 6/2016 | Corbus Pharmaceuticals | Post-IPO Equity | 14.8M |
| 3/2018 | Molecular Templates | Post-IPO Debt | 10M |
| 3/2020 | Zucara Therapeutics | Series A | 21M |
| 3/2021 | Absci | Venture Round | 0 |
| 8/2018 | Renovia | Series B | 32.3M |
| 2/2018 | Partner Therapeutics | Series A | 60M |
| 1/2019 | Vyome Therapeutics | Series D | 22M |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 8/2016 | Aquestive Therapeutics | Debt Financing | 50M |
| 7/2019 | AgaMatrix | Debt Financing | 56M |
| 8/2017 | Dova Pharmaceuticals | Post-IPO Equity | - |
| 5/2017 | Synlogic | Series C | 42M |
| 7/2020 | Genome Medical | Series B | 0 |
| 8/2020 | ReViral | Series C | 0 |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 4/2022 | Surf Bio | Seed | 16M |
| 7/2015 | Outlook Therapeutics | Venture Round | 31M |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 12/2005 | EUSA Pharma | Venture Round | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 6/2015 | Alliqua BioMedical | Post-IPO Debt | 15.5M |
| 9/2014 | Affimed | Debt Financing | 14M |
| 11/2020 | Adagio Medical | Series E | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 4/2020 | COMPASS Pathways | Series B | 0 |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 9/2021 | Emulate | Series E | 82M |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 9/2020 | Willow | Series C | 0 |
| 5/2017 | Home Dialysis Plus | Series C | 76.5M |
| 4/2021 | Forge Biologics | Series B | 120M |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 7/2019 | Frequency Therapeutics | Series C | 0 |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 10/2021 | Honor | Debt Financing | 300M |
| 9/2018 | Lyra Therapeutics | Series B | 0 |
| 1/2016 | Arno Therapeutics | Post-IPO Equity | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 9/2021 | Hancock Jaffe Laboratories | Post-IPO Equity | 20M |
| 7/2018 | Alector | Series E | 133M |
| 8/2016 | Arno Therapeutics | Post-IPO Equity | 8M |
| 3/2020 | immatics biotechnologies | Post-IPO Equity | 0 |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 12/2019 | Quellis Biosciences | Series A | 0 |
| 7/2014 | Virobay | Series B | 8M |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 1/2022 | Orchestra BioMed | Series D | 0 |
| 9/2021 | A-Alpha Bio | Series A | 20M |
| 1/2022 | AvengeBio | Series A | 0 |
| 6/2019 | PanTheryx | Venture Round | 50M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 2/2020 | Agile Therapeutics | Post-IPO Debt | 20M |
| 5/2017 | Xontogeny | Series A | 15M |
| 5/2019 | ArcherDX | Series B | 60M |
| 3/2015 | Champions Oncology | Post-IPO Equity | 14M |
| 7/2019 | Neptune Wellness Solutions | Post-IPO Equity | 41.4M |
| 11/2015 | Solid Biosciences | Series B | 42.5M |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 9/2018 | Vapotherm | Series D | 0 |
| 11/2020 | Prometheus Biosciences | Equity | 130M |
| 4/2020 | Dynacure | Series C | 54.2M |
| 12/2019 | ArcherDX | Series C | 0 |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 9/2020 | Zymergen | Series D | 300M |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 1/2021 | Earli | Series A | 40M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 10/2021 | Twin Health | Series C | 155M |
| 1/2021 | Impulse Dynamics | Series D | 60M |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 5/2017 | Outset Medical | Series C | 0 |
| 11/2017 | Counsyl | Equity | 80M |
| 5/2021 | Cue | Venture Round | 235M |
| 6/2020 | DNAnexus | Series G | 0 |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 5/2020 | Nautilus Biotechnology | Series B | 76M |
| 3/2019 | Saama | Venture Round | 40M |
| 6/2016 | VitalConnect | Series B | 18M |
| 10/2020 | LianBio | Series A | 0 |
| 7/2018 | Athenex | Post-IPO Equity | 50M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 4/2019 | Kindbody | Series A | 15M |
| 1/2020 | Sonendo | Venture Round | 85M |
| 12/2016 | VBI Vaccines | Post-IPO Equity | 10.6M |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 4/2017 | Singulex | Debt Financing | 50M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 12/2016 | VBI Vaccines | Post-IPO Debt | 13M |
| 1/2018 | AEGEA Medical | Series D | 0 |
| 1/2021 | Clover Health | Post-IPO Equity | 400M |
| 6/2020 | C4 Therapeutics | Debt Financing | 20M |
| 5/2018 | Rain Therapeutics | Series A | 18.4M |
| 9/2022 | InSightec | Debt Financing | 100M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 8/2020 | Freenome | Series C | 270M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 8/2018 | Outset Medical | Series D | 0 |
| 8/2016 | Vyome Therapeutics | Series C | 14M |
| 8/2021 | Bridge to Life | Venture Round | 56M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 5/2020 | Omada Health | Venture Round | 57M |
| 2/2019 | ADMA Biologics | Post-IPO Debt | 72.5M |
| 9/2022 | SpringWorks Therapeutics | Post-IPO Equity | 225M |
| 9/2017 | Landos Biopharma | Series A | 10M |
| 10/2014 | Zynerba Pharmaceuticals | Venture Round | 13M |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 7/2020 | Pear Therapeutics | Debt Financing | 50M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 1/2018 | Vitruvias Therapeutics | Series A | 11.5M |
| 10/2013 | Arno Therapeutics | Post-IPO Equity | 0 |
| 3/2021 | Scribe Therapeutics | Series B | 100M |
| 6/2015 | Outset Medical | Debt Financing | 45M |
| 8/2018 | ReViral | Series B | 0 |
| 7/2016 | VBI Vaccines | Post-IPO Equity | 0 |
| 12/2021 | Freenome | Series D | 300M |
| 11/2021 | Sermonix | Series A | 40M |
| 9/2016 | Establishment Labs | Debt Financing | 15M |
| 5/2019 | Athenex | Post-IPO Equity | 100M |
| 9/2015 | Outlook Therapeutics | Venture Round | - |
| 1/2021 | Affinivax | Series C | 226M |
| 4/2018 | Kodiak Sciences | Convertible Note | 33M |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 7/2019 | Foamix | Post-IPO Debt | 64M |
| 6/2020 | AsclepiX Therapeutics | Series A | 35M |
| 3/2022 | VivoSense | Series A | 0 |
| 1/2021 | DarioHealth | Post-IPO Equity | 70M |
| 11/2022 | Biodesix | Post-IPO Debt | 50M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 8/2017 | Molecular Templates | Post-IPO Equity | 60M |
| 7/2019 | Kronos Bio | Series A | 105M |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 12/2016 | Motus GI | Venture Round | 0 |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 12/2020 | Neuron23 | Series B | 80M |
| 12/2016 | Vensun Pharmaceuticals | Series C | 22.5M |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 5/2020 | Atea | Series D | 215M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 7/2020 | Kindbody | Series B | 0 |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 10/2020 | AavantiBio | Series A | 0 |
| 1/2020 | Lyra Therapeutics | Series C | 0 |
| 5/2007 | Spectrum Pharmaceuticals | Post-IPO Equity | 0 |
| 3/2022 | DNAnexus | Series H | 200M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 7/2020 | Forge Biologics | Series A | 40M |
| 5/2021 | Juno Diagnostics | Series A | 25M |
| 2/2022 | Synthego | Series E | 0 |
| 3/2019 | Orchestra BioMed | Series B | 34M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 7/2019 | Beta Bionics | Series B | 63M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 10/2014 | Invitae | Series F | 0 |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 11/2015 | Vapotherm | Series C | 0 |
| 4/2019 | SpringWorks Therapeutics | Series B | 125M |
| 7/2019 | Freenome | Series B | 160M |
| 2/2022 | Endeavor BioMedicines | Series B | 101M |
| 8/2021 | Genome Medical | Series C | 0 |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 5/2021 | Affinia Therapeutics | Series B | 0 |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 4/2014 | Otonomy | Series D | 49M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
| 4/2021 | Icosavax | Series B | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 6/2019 | Genome Medical | Series B | 23M |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 3/2022 | Neuron23 | Series C | 0 |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 5/2023 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 6/2021 | Kindbody | Series C | 0 |
| 5/2019 | Confo Therapeutics | Series A | 33.6M |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
| 5/2017 | Vapotherm | Series D | 0 |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 1/2021 | MIVI Neuroscience | Series B | 35M |
| 3/2021 | Crossover Health | Series D | 0 |
| 9/2021 | HilleVax | Equity | 135M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 12/2021 | Hyperfine | Post-IPO Equity | 0 |
| 3/2021 | OnKure | Series B | 56.6M |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 1/2016 | Zymeworks | Series A | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 8/2020 | Metabolon | Venture Round | 72M |
| 3/2010 | Sevion Therapeutics | Post-IPO Equity | 0 |
| 9/2018 | Allogene | Convertible Note | 0 |
| 6/2020 | CereVasc | Series A | 44M |
| 8/2022 | MeiraGTx | Post-IPO Debt | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 4/2022 | Surf Bio | Seed Round | 0 |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | VivoSense | Series A | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 3/2022 | DNAnexus | Series H | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
